Preparation, in vitro anti-tumour activity and in vivo pharmacokinetics of RGD-decorated liposomes loaded with shikonin

References

• Administration F D.USFDA. 2001. Guidance for industry: bioanalytical method validation. http://www.fda.gov./cder/guidance/4252fnl.pdf,66.
   Google Scholar
• Awasthi VD, Garcia D, Goins BA, Phillips WT. 2003. Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int J Pharm. 253(1-2):121–132. doi: 10.1016/s0378-5173(02)00703-2.
   PubMed Web of Science ®Google Scholar
• Bozzuto G, Molinari A. 2015. Liposomes as nanomedical devices. Int J Nanomedicine. 10:975–999. doi: 10.2147/IJN.S68861.
   PubMed Web of Science ®Google Scholar
• Breslin S, O'Driscoll L. 2013. Three-dimensional cell culture: the missing link in drug discovery. Drug Discov Today. 18(5-6):240–249. doi: 10.1016/j.drudis.2012.10.003.
   PubMed Web of Science ®Google Scholar
• Brooks PC, Clark RA, Cheresh DA. 1994. Requirement of vascular integrin alphav-beta3 for angiogenesis. Science. 264(5158):569–571. doi: 10.1126/science.7512751.
   PubMed Web of Science ®Google Scholar
• Cai W, Geng C, Jiang L, Sun J, Chen B, Zhou Y, Yang B, Lu H. 2020. Encapsulation of gemcitabine in RGD-modified nanoliposomes improves breast cancer inhibitory activity. Pharm Dev Technol. 25(5):640–648. doi: 10.1080/10837450.2020.1727920.
   PubMed Web of Science ®Google Scholar
• Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, Khorasani S, Mozafari M. 2018. Impact of particle size and polydispersity index on the clinical applications of lipidic nano-carrier systems. Pharmaceutics. 10(2):57. doi: 10.3390/pharmaceutics10020057.
   PubMed Web of Science ®Google Scholar
• Deng Z, Wang X, Wang F, Qin Z, Cui Y, Sun Y, Sun L. 2016. Pharmacokinetics and tissue distribution study of 16-dehydropregnenolone liposome in female mice after intravenous administration. Drug Deliv. 23(8):2787–2795. doi: 10.3109/10717544.2015.1088596.
   PubMed Web of Science ®Google Scholar
• Guo H, Sun J, Li D, Hu Y, Yu X, Hua H, Jing X, Chen F, Jia Z, Xu J. 2019. Shikonin attenuates acetaminophen-induced acute liver injury via inhibition of oxidative stress and inflammation. Biomed Pharmacother. 112:108704–108712. doi: 10.1016/j.biopha.2019.108704.
   PubMed Web of Science ®Google Scholar
• Guo C, He J, Song X, Tan L, Wang M, Jiang P, Li Y, Cao Z, Peng C. 2019. Pharmacological properties and derivatives of shikonin-A review in recent years. Pharmacol Res. 149:104463. doi: 10.1016/j.phrs.2019.104463.
   PubMed Web of Science ®Google Scholar
• Han B, Yang Y, Chen J, Tang H, Sun Y, Zhang Z, Wang Z, Li Y, Li Y, Luan X, et al. 2020. Preparation, characterization, and pharmacokinetic study of a novel long-acting targeted paclitaxel liposome with anti-tumor activity. Int J Nanomedicine. 15:553–571. doi: 10.2147/IJN.S228715.
   PubMed Web of Science ®Google Scholar
• Hao Z, Qian J, Yang J. 2015. Shikonin induces apoptosis and inhibits migration of ovarian carcinoma cells by inhibiting the phosphorylation of Src and FAK. Oncol Lett. 9(2):629–633. doi: 10.3892/ol.2014.2771.
   PubMed Web of Science ®Google Scholar
• Hartwig F, Köll-Weber M, Süss R. 2021. Preclinical In vitro studies with 3D spheroids to evaluate Cu(DDC)2 containing ciposomes for the treatment of teuroblastoma. Pharmaceutics. 13(6):894. doi: 10.3390/pharmaceutics13060894.
   PubMed Web of Science ®Google Scholar
• Huang S, Yu L, Shen P. 2010. Simultaneous quantitative analysis of shikonin and deoxyshikonin in rat plasma by rapid LC-ESI-MS-MS. Chroma. 72(1-2):63–69. doi: 10.1365/s10337-010-1599-5.
   Web of Science ®Google Scholar
• Huang Z, Lv F, Wang J, Cao S, Liu Z, Liu Y, Lu W. 2019. RGD-modified PEGylated paclitaxel nanocrystals with enhanced stability and tumor-targeting capability. Int J Pharm. 556:217–225. doi: 10.1016/j.ijpharm.2018.12.023.
   PubMed Web of Science ®Google Scholar
• Janos S, Lajos B, Sandor S, Mihaly B, Morse DS, Milan B, Stahl GL, Rolf B, Alving CR. 2000. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am J Physiol. 279(3):1319–1328.
   Google Scholar
• Jiang L, Li L, He X, Yi Q, He B, Cao J, Pan W, Gu Z. 2015. Overcoming drug resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response. Biomaterials. 52:126–139. doi: 10.1016/j.biomaterials.2015.02.004.
   PubMed Web of Science ®Google Scholar
• Khabazian E, Vakhshiteh F, Norouzi P, Fatahi Y, Dinarvand R, Atyabi F. 2022. Cationic liposome decorated with cyclic RGD peptide for targeted delivery of anti-STAT3 siRNA to melanoma cancer cells. J Drug Target. 30(5):522–533. doi: 10.1080/1061186X.2021.1973481.
   PubMed Web of Science ®Google Scholar
• Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H. 2011. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release. 153(2):141–148. doi: 10.1016/j.jconrel.2011.03.012.
   PubMed Web of Science ®Google Scholar
• Li M, Chen X, Hu S, Wang R, Peng X, Bai X. 2018. Determination of blood concentrations of main active compounds in Zi-Cao-Cheng-Qi decoction and their total plasma protein binding rates based on hollow fiber liquid phase microextraction coupled with high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 1072:355–361. doi: 10.1016/j.jchromb.2017.11.046.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang R, Zhang D, Zhang C, Zhang Z, Fu X, Luo Y, Chen S, Wu A, Zeng W, et al. 2022. Cyclic RGD-decorated liposomal gossypol AT-101 targeting for enhanced anti-tumor effect. Int J Nanomedicine. 17:227–244. doi: 10.2147/IJN.S341824.
   PubMed Web of Science ®Google Scholar
• Liu P, Chen G, Zhang J. 2022. A Review of Liposomes as a Drug Delivery System: current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules. 27(4):1372. doi: 10.3390/molecules27041372.
   PubMed Web of Science ®Google Scholar
• Luo L, Zheng P, Nie H, Chen Y, Tong D, Chen J, Cheng Y. 2016. Pharmacokinetics and tissue distribution of docetaxel liposome mediated by a novel galactosylated cholesterol derivatives synthesized by lipase-catalyzed esterification in non-aqueous phase. Drug Deliv. 23(4):1282–1290. doi: 10.3109/10717544.2014.980525.
   PubMed Web of Science ®Google Scholar
• Maeda H, Matsumura Y. 2011. EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy. Adv Drug Deliv Rev. 63(3):129–130. doi: 10.1016/j.addr.2010.05.001.
   PubMed Web of Science ®Google Scholar
• Men W, Zhu P, Dong S, Liu W, Zhou K, Bai Y, Liu X, Gong S, Zhang S. 2020. Layer-by-layer pH-sensitive nanoparticles for drug delivery and controlled release with improved therapeutic efficacy in vivo. Drug Deliv. 27(1):180–190. doi: 10.1080/10717544.2019.1709922.
   PubMed Web of Science ®Google Scholar
• Perche F, Torchilin VP. 2012. Cancer cell spheroids as a model to evaluate chemotherapy protocols. Cancer Biol Ther. 13(12):1205–1213. doi: 10.4161/cbt.21353.
   PubMed Web of Science ®Google Scholar
• Rivas Mercado E, Neri Castro E, Bénard Valle M, Rucavado-Romero A, Olvera Rodríguez A, Zamudio Zuñiga F, Alagón Cano A, Garza Ocañas L. 2020. Disintegrins extracted from totonacan rattlesnake (Crotalus totonacus) venom and their anti-adhesive and anti-migration effects on MDA-MB-231 and HMEC-1 cells. Toxicol in Vitro. 65:104809. doi: 10.1016/j.tiv.2020.104809.
   PubMed Web of Science ®Google Scholar
• Ren Y, Yuan B, Hou S, Sui Y, Yang T, Lv M, Zhou Y, Yu H, Li S, Peng H, et al. 2021. Delivery of RGD-modified liposome as a targeted colorectal carcinoma therapy and its autophagy mechanism. J Drug Target. 29(8):863–874. doi: 10.1080/1061186X.2021.1882469.
   PubMed Web of Science ®Google Scholar
• Shan D, Li J, Cai P, Prasad P, Liu F, Rauth A, Wu X. 2015. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells. Drug Deliv Transl Res. 5(1):15–26. doi: 10.1007/s13346-014-0210-2.
   PubMed Web of Science ®Google Scholar
• Shao YY, Yin Y, Lian BP, Leng JF, Xia YZ, Kong LY. 2020. Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site. Eur J Med Chem. 190:112105. doi: 10.1016/j.ejmech.2020.112105.
   PubMed Web of Science ®Google Scholar
• Sheikh A, Alhakamy NA, Md S, Kesharwani P. 2021. Recent progress of RGD modified liposomes as multistage rocket against cancer. Front Pharmacol. 12:803304. doi: 10.3389/fphar.2021.803304.
   PubMed Web of Science ®Google Scholar
• Song Z, Lin Y, Zhang X, Feng C, Lu Y, Gao Y, Dong C. 2017. Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects. Int J Nanomedicine. 12:1941–1958. doi: 10.2147/IJN.S125573.
   PubMed Web of Science ®Google Scholar
• Su Y, Huang N, Chen D, Zhang L, Dong X, Sun Y, Zhu X, Zhang F, Gao J, Wang Y, et al. 2017. Successful in vivo hyperthermal therapy toward breast cancer by Chinese medicine shikonin-loaded thermosensitive micelle. Int J Nanomedicine. 12:4019–4035. doi: 10.2147/IJN.S132639.
   PubMed Web of Science ®Google Scholar
• Sun J, Jiang L, Lin Y, Gerhard EM, Jiang X, Li L, Yang J, Gu Z. 2017. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides. Int J Nanomedicine. 12:1517–1537. doi: 10.2147/IJN.S122859.
   PubMed Web of Science ®Google Scholar
• Tchoryk A, Taresco V, Argent RH, Ashford M, Gellert PR, Stolnik S, Grabowska A, Garnett MC. 2019. Penetration and uptake of nanoparticles in 3D tumor spheroids. Bioconjug Chem. 30(5):1371–1384. doi: 10.1021/acs.bioconjchem.9b00136.
   PubMed Web of Science ®Google Scholar
• Toro-Cordova A, Flores-Cruz M, Santoyo-Salazar J, Carrillo-Nava E, Jurado R, Figueroa-Rodriguez PA, Lopez-Sanchez P, Medina LA, Garcia-Lopez P. 2018. Liposomes loaded with cisplatin and magnetic nanoparticles: physicochemical characterization, pharmacokinetics, and in-vitro efficacy. Molecules. 23(9):2272. doi: 10.3390/molecules23092272.
   PubMed Web of Science ®Google Scholar
• US. 2001. Guidance for industry on bioanalytical method validation. Department of Health and Human Services (DHHS), Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM). Available from: http://www/fda.gov/cder/guidance/index.htm. [last accessed 18 Apr 2015].
   Google Scholar
• Wang F, Yao X, Zhang Y, Tang J. 2019. Synthesis, biological function and evaluation of shikonin in cancer therapy. Fitoterapia. 134:329–339. doi: 10.1016/j.fitote.2019.03.005.
   PubMed Web of Science ®Google Scholar
• Wei T, Liu J, Ma H, Cheng Q, Huang Y, Zhao J, Huo S, Xue X, Liang Z, Liang X. 2013. Functionalized nanoscale micelles improve drug delivery for cancer therapy in vitro and in vivo. Nano Lett. 13(6):2528–2534. doi: 10.1021/nl400586t.
   PubMed Web of Science ®Google Scholar
• Wen X, Li J, Cai D, Yue L, Wang Q, Zhou L, Fan L, Sun J, Wu Y. 2018. Anticancer efficacy of targeted shikonin liposomes modified with RGD in breast cancer cells. Molecules. 23(2):268. doi: 10.3390/molecules23020268.
   PubMed Web of Science ®Google Scholar
• Xiao K, Li Y, Luo J, Lee JS, Xiao W, Gonik AM, Agarwal RG, Lam KS, Joyce. 2011. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials. 32(13):3435–3446., doi: 10.1016/j.biomaterials.2011.01.021.
   PubMed Web of Science ®Google Scholar
• Yingchoncharoen P, Kalinowski DS, Richardson DR. 2016. Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol Rev. 68(3):701–787. doi: 10.1124/pr.115.012070.
   PubMed Web of Science ®Google Scholar
• Zhang F, Pan T, Wu X, Gao X, Li Z, Ren X. 2020. Non-cytotoxic doses of shikonin inhibit lipopolysaccharide-induced TNF-α expression via activation of the AMP-activated protein kinase signaling pathway. Exp Ther Med. 20(5):45. doi: 10.3892/etm.2020.9173.
   PubMed Web of Science ®Google Scholar
• Zhao F, Li L, Guan L, Yang H, Wu C, Liu Y. 2014. Roles for GP IIb/IIIa and αvβ3 integrins in MDA-MB-231 cell invasion and shear flow-induced cancer cell mechanotransduction. Cancer Lett. 344(1):62–73. doi: 10.1016/j.canlet.2013.10.019.
   PubMed Web of Science ®Google Scholar
• Zhong G, Sha L, Liu Z, Wei X. 2018. Tumor-penetrating peptide-functionalized redox-responsive hyperbranched poly(amido amine) delivering sirna for lung cancer therapy. ACS Biomater Sci Eng. 4(3):988–996. doi: 10.1021/acsbiomaterials.7b00971.
   PubMed Web of Science ®Google Scholar
• Zhou J, Guo B, Zhu W, Sui X, Han C. 2020. Novel biomimetic nanostructured lipid carriers for cancer therapy: preparation, characterization, and in vitro/in vivo evaluation. Pharmaceutical Development and Technology. 26(7):1–11.
   PubMedGoogle Scholar
• Zhou T, Tang X, Zhang W, Feng J, Wu W. 2019. Preparation and in vitro and in vivo evaluations of 10-hydroxycamptothecin liposomes modified with stearyl glycyrrhetinate. Drug Deliv. 26(1):673–679. doi: 10.1080/10717544.2019.1636422.
   PubMed Web of Science ®Google Scholar
• Zuo H. 2019. iRGD: a promising peptide for cancer imaging and a potential therapeutic agent for various cancers. J Oncol. 2019:9367845. doi: 10.1155/2019/9367845.
   PubMed Web of Science ®Google Scholar